Inmune Bio, Inc. announced it raised $3.34 Million in an initial filing from an offering of $5 Million
Inmune Bio, Inc. announced it raised $3.34 Million in an initial filing from an offering of $5 Million
07/13/17, 6:19 PM
Location
Money raised
$3.34 million
Round Type
seed
Company Info
Location
1224 prospect street
la jolla, california, united states
Additional Info
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (QuellorTM), cancer (INB03TM), Alzheimer's and Treatment Resistant Depression (XPro1595), and NASH (LIVNateTM). The Natural Killer Cell Priming Platform includes INKmuneTM aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.